FDA Fast Track for Pelareorep in Anal Cancer

On July 20, 2026, Oncolytics Biotech Inc. announced that the U.S. United States — Food and Drug Administration (FDA) granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on or were intolerant to prior systemic therapy. This is the third Fast Track designation for pelareorep in gastrointestinal cancers, following designations in KRAS-mutated metastatic colorectal cancer (February 2026) and pancreatic cancer (2022). The designation is supported by data from the GOBLET study showing an objective response rate of approximately 30%, median duration of response of 15.5 months, and 12-month overall survival rate of 82%. The company estimates the U.S. commercial opportunity for this indication at nearly $1 billion annually. Oncolytics has a clear regulatory framework for a pivotal study following positive FDA feedback in April 2026. However, the company's cash resources as of March 31, 2026 were $5.49 million, raising substantial doubt about its ability to continue as a going concern.